Obtaining consistent efficacy beyond 12–24 hours with local anesthetics, including extended-release formulations, has been a challenging goal. Inflammation following surgery lowers the pH of affected tissues, reducing neuronal penetration of local anesthetics. HTX-011, a local anesthetic combining bupivacaine and low-dose meloxicam was developed to reduce postsurgical pain through 72 hours using novel extended-release polymer technology.
This webinar reviews preclinical and clinical data confirming the mechanism of action for HTX-011.
